This site is intended for U.S. healthcare professionals.

Visit Pfizer MedicalVisit Pfizer MedicalLoading

Menu

Close

Sign InLog Out ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact

Menu

Close

About HYMPAVZIAbout
HYMPAVZIOverviewHYMPAVZI in ActionEfficacyEfficacyStudy DesignPrimary EndpointsSecondary EndpointsSafetyDosing & AdminDosing 

& AdminDosingPen OverviewInjection OverviewPatient ProfilesPatient
ProfilesIdentifying PatientsUnmet NeedsResourcesResourcesResourcesPatient Savings & Support
Full Prescribing InformationPatient InformationInstructions for UseIndication Patient Site
Prefilled pen. Fixed dose.* Once weekly.1Prefilled pen. Fixed dose.* Once weekly.1
Dosing schedule
Dosing schedule
A dose adjustment to 300 mg subcutaneous injection weekly can be considered in patients weighing ≥50 kg when control of bleeding events is judged to be inadequate by the healthcare provider. Safety and efficacy of HYMPAVZI at doses above 300 mg weekly have not been established.1Rotate the injection site with each injection. For full instructions, read the Instructions for Use.1
View Instructions for Use
LoadingDosing that may fit your patients’ individual lifestylesDosing that may fit your patients’ individual lifestyles
  • The same prefilled dose every week means consistent dosing with no mixing, measuring, or lengthy prep1
  • Regardless of weight or activity level, patients take the same dose every week after their initial loading dose1
  • Subcutaneous injection means no venous access required. HYMPAVZI should not be injected into the veins1
 Flexible storage and portability
  • The HYMPAVZI pen is stored in the refrigerator (36°F to 46°F)1
  • It can be removed from the refrigerator and stored at room temperature (up to 86°F) in its original carton for up to 7 days1
  • Once reaching room temperature, HYMPAVZI must not be returned to refrigerated storage and must be used or discarded after 7 days1
  • Keep the HYMPAVZI pen out of direct sunlight1
  • Do not freeze1
  • The same prefilled dose every week means consistent dosing with no mixing, measuring, or lengthy prep1
  • Regardless of weight or activity level, patients take the same dose every week after their initial loading dose1
  • Subcutaneous injection means no venous access required. HYMPAVZI should not be injected into the veins1
 Flexible storage and portability
  • The HYMPAVZI pen is stored in the refrigerator (36°F to 46°F)1
  • It can be removed from the refrigerator and stored at room temperature (up to 86°F) in its original carton for up to 7 days1
  • Once reaching room temperature, HYMPAVZI must not be returned to refrigerated storage and must be used or discarded after 7 days1
  • Keep the HYMPAVZI pen out of direct sunlight1
  • Do not freeze1
Meet the HYMPAVZI penLoading Meet the HYMPAVZI pen Loading

HYMPAVZI is intended for use under the guidance of a healthcare provider. After proper training in subcutaneous injection technique, a patient may self-inject, or the patient’s caregiver may administer HYMPAVZI, if a healthcare provider determines that it is appropriate.1

HYMPAVZI is intended for use under the guidance of a healthcare provider. After proper training in subcutaneous injection technique, a patient may self-inject, or the patient’s caregiver may administer HYMPAVZI, if a healthcare provider determines that it is appropriate.1

SC=subcutaneous.The recommended dosage of HYMPAVZI on day 1 is a loading dose of 300 mg (two 150 mg pens) by subcutaneous injection. On day 8 and thereafter, the weekly maintenance dose is 150 mg (one pen) by subcutaneous injection.1Reference:1. HYMPAVZI. Prescribing Information. Pfizer Inc.; 2024.Dosing & AdminDosing & Admin Who is the appropriate HYMPAVZI patient?

Uncover the unmet needs and lifestyle considerations that may make patients candidates for HYMPAVZI

See patient profiles
LoadingHYMPAVZI is a trademark of Pfizer Inc.HYMPAVZI is a trademark of Pfizer Inc.

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2025 Pfizer Inc. All rights reserved.

PP-HYM-USA-0073
Indications and usageHYMPAVZI is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with:
 
  • hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors, or
  • hemophilia B (congenital factor IX deficiency) without factor IX inhibitors.
Helix ISI Modal Headline Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Important Safety InformationHYMPAVZI is a tissue factor pathway inhibitor (TFPI) antagonist and may increase the risk of thromboembolic complications. Interrupt HYMPAVZI prophylaxis if diagnostic findings consistent with thromboembolism occur and manage as clinically indicated. If factor VIII or factor IX products are indicated in a patient receiving HYMPAVZI prophylaxis, the minimum effective dose of factor VIII or factor IX according to the product label is recommended.

HYMPAVZI may cause hypersensitivity reactions (including, but not limited to, urticaria and pruritus). If HYMPAVZI-treated patients develop a severe hypersensitivity reaction, advise patients to discontinue HYMPAVZI and seek immediate emergency treatment.

Based on its mechanism of action, HYMPAVZI may cause fetal harm when administered to a pregnant woman. Verify that females of reproductive potential are not pregnant prior to initiating HYMPAVZI. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment with HYMPAVZI and for 2 months after the last dose.

A serious adverse reaction of peripheral swelling occurred in one patient. Adverse reactions reported in ≥3% of patients treated with HYMPAVZI in clinical trials included injection site reaction (9% of patients); headache (7% of patients); pruritus (3% of patients).IndicationHYMPAVZI is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with:
  • hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors, or
  • hemophilia B (congenital factor IX deficiency) without factor IX inhibitors.